Cookies
We use essential cookies to run the site. Analytics cookies are optional and help us improve World Wide. Learn more.
Professor
Department of Clinical Neurosciences, University of Cambridge
Showing your local timezone
Schedule
Tuesday, February 14, 2023
3:00 PM Europe/London
Recording provided by the organiser.
Domain
NeuroscienceHost
Cambridge Neuro
Duration
70 minutes
Current disease-modifying therapies in multiple sclerosis are all focused on suppressing the inflammatory phase of the disease. This has been extremely successful, and it is doubtful that significantly more efficacious anti-inflammatory treatments will be found. However, it remains the case that people with relapsing-remitting multiple sclerosis acquire disability on treatment, and enter the secondary progressive phase. I argue that we now need treatments that prevent neuronal degeneration. The most promising approach is to prevent axons degenerating by remyelination. Since the discovery that the adult brain contains stem cells which can remyelinate, the problem now is how to promote endogenous remyelination, and how to know when we have achieved this! We have successfully identified one drug which promotes remyelination but unfortunately it is too toxic for use in the clinic. So the hunt continues.
Alasdair Coles
Professor
Department of Clinical Neurosciences, University of Cambridge
neuro
Digital Minds: Brain Development in the Age of Technology examines how our increasingly connected world shapes mental and cognitive health. From screen time and social media to virtual interactions, t
neuro
neuro
Alpha synuclein and Lrrk2 are key players in Parkinson's disease and related disorders, but their normal role has been confusing and controversial. Data from acute gene-editing based knockdown, follow